Insider Transactions in Q1 2024 at Myriad Genetics Inc (MYGN)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 25
2024
|
Natalie Munk Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
363
-0.8%
|
$7,623
$21.98 P/Share
|
|
Mar 24
2024
|
Paul J Diaz President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
45,822
-1.72%
|
$1,008,084
$22.24 P/Share
|
|
Mar 24
2024
|
Mark Verratti Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,245
-0.54%
|
$71,390
$22.24 P/Share
|
|
Mar 24
2024
|
Dale Muzzey Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
943
-0.42%
|
$20,746
$22.24 P/Share
|
|
Mar 24
2024
|
Kevin Richard Haas Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,890
-1.08%
|
$63,580
$22.24 P/Share
|
|
Mar 24
2024
|
Natalie Munk Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
981
-1.06%
|
$21,582
$22.24 P/Share
|
|
Mar 22
2024
|
Paul J Diaz President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
20,202
-1.49%
|
$444,444
$22.24 P/Share
|
|
Mar 22
2024
|
Mark Verratti Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,648
-0.54%
|
$36,256
$22.24 P/Share
|
|
Mar 22
2024
|
Dale Muzzey Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,405
-1.24%
|
$30,910
$22.24 P/Share
|
|
Mar 22
2024
|
Kevin Richard Haas Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,685
-1.23%
|
$37,070
$22.24 P/Share
|
|
Mar 22
2024
|
Margaret Ancona SVP, Chief of Staff |
SELL
Payment of exercise price or tax liability
|
Direct |
730
-0.8%
|
$16,060
$22.24 P/Share
|
|
Mar 22
2024
|
Natalie Munk Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
363
-0.78%
|
$7,986
$22.24 P/Share
|
|
Mar 22
2024
|
Pamela Wong Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,441
-2.17%
|
$31,702
$22.24 P/Share
|
|
Mar 15
2024
|
Mark Verratti Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,686
-1.2%
|
$77,406
$21.16 P/Share
|
|
Mar 15
2024
|
Dale Muzzey Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,322
-2.85%
|
$69,762
$21.16 P/Share
|
|
Mar 15
2024
|
Kevin Richard Haas Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,306
-2.36%
|
$69,426
$21.16 P/Share
|
|
Mar 15
2024
|
Margaret Ancona SVP, Chief of Staff |
SELL
Payment of exercise price or tax liability
|
Direct |
1,585
-1.7%
|
$33,285
$21.16 P/Share
|
|
Mar 15
2024
|
Pamela Wong Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,568
-3.72%
|
$53,928
$21.16 P/Share
|
|
Mar 15
2024
|
Paul J Diaz President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
30,610
-2.2%
|
$642,810
$21.16 P/Share
|
|
Mar 14
2024
|
Scott J. Leffler Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
46,095
+21.95%
|
-
|
|
Mar 14
2024
|
Samraat S. Raha Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
64,494
+17.65%
|
-
|
|
Mar 14
2024
|
Mark Verratti Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
58,631
+15.98%
|
-
|
|
Mar 14
2024
|
Dale Muzzey Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
49,250
+29.67%
|
-
|
|
Mar 14
2024
|
Shereen Solaiman Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
41,042
+42.38%
|
-
|
|
Mar 14
2024
|
Kevin Richard Haas Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,178
+20.08%
|
-
|
|
Mar 14
2024
|
Margaret Ancona SVP, Chief of Staff |
BUY
Grant, award, or other acquisition
|
Direct |
35,178
+27.4%
|
-
|
|
Mar 14
2024
|
Natalie Munk Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,500
+13.83%
|
-
|
|
Mar 14
2024
|
Paul J Diaz President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
246,248
+15.04%
|
-
|
|
Mar 01
2024
|
Shereen Solaiman Chief People Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,108
-6.99%
|
$24,376
$22.18 P/Share
|
|
Feb 25
2024
|
Kevin Richard Haas Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
881
-0.83%
|
$19,382
$22.72 P/Share
|
|
Feb 25
2024
|
Margaret Ancona SVP, Chief of Staff |
SELL
Payment of exercise price or tax liability
|
Direct |
2,231
-3.7%
|
$49,082
$22.72 P/Share
|
|
Jan 29
2024
|
Scott J. Leffler Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
117,770
+50.0%
|
-
|
|
Jan 01
2024
|
Dale Muzzey Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
303
-0.45%
|
$5,757
$19.14 P/Share
|